Form 8-K Verrica Pharmaceuticals For: Aug 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Verrica Pharmaceuticals (VRCA) PT Lowered to $13 at RBC Capital
August 15, 2024 6:16 AM EDTRBC Capital analyst Daniel Busby lowered the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $13.00 (from $14.00) while maintaining a Outperform rating.
The analyst comments "VRCA's 2Q report shows steady progress for YCANTH through its molluscum contagiosum launch as distribution network expands; although aspects such as... More
